Piper Sandler Remains Bullish on Compass Therapeutics (CMPX)

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best stocks under $5 with highest upside potential. Compass Therapeutics Inc. (NASDAQ:CMPX) received a rating update from Piper Sandler analyst Biren Amin on October 27, who maintained a Buy rating on the stock with a $12 price target.

Is Compass Therapeutics, Inc. (CMPX)The Hot Biotech Stock Under $5?

Similarly, LifeSci Capital analyst Charles Zhu also expressed bullish sentiments for Compass Therapeutics Inc. (NASDAQ:CMPX) on October 17, reiterating a Buy rating with a $10 price target.

Zhu cited the promising progress of the company’s COMPANION-002 trial, which is testing tovecimig for second-line biliary tract cancer (BTC) patients. The trial exhibited potential clinical benefits with a median follow-up of around 19 months, which the analyst considers notable since it exceeds the overall survival rates shown by other similar studies.

In addition to this positive outlook for the treatment, Zhu expects the anticipated pricing strategy for tovecimig to offer financial upside, with both domestically and internationally ongoing regulatory engagements further expected to bolster future growth prospects.

Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics. The company’s platform includes human display for antibody tuning, common light chain-focused antibody discovery, stitchmabs, and highly modular and manufacturable bispecific candidates.

While we acknowledge the potential of CMPX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CMPX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.